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In order to improve the immunogenicity of HIV-1 envelope glycoproteins, we have fused gp120 to a carrier protein, hepatitis B surface
antigen (HBsAg), which is capable of spontaneous assembly into virus-like particles. The HBsAg-gp120 hybrid proteins assembled
efficiently into 20–30 nm particles. The particles resemble native HBsAg particles in size and density, consistent with a lipid composition of
about 25% and a gp120 content of about 100 per particle. Particulate gp120 folds in its native conformation and is biologically active, as
shown by high affinity binding of CD4. The particles express conformational determinants targeted by a panel of broadly cross-reactive
neutralizing antibodies, and they show tight packing of gp120. Because the particles are lipoprotein micelles, an array of gp120 on their
surface closely mimics gp120 on the surface of HIV-1 virions. These gp120-rich particles can enhance the quality, as well as quantity, of
antibodies elicited by a gp120 vaccine.
Published by Elsevier Inc.Keywords: Virus-like particles; HIV-1; Envelope glycoprotein gp120Introduction
HIV-1 infection induces a strong immune response in
humans, including the production of cross-reactive neutral-
izing antibodies (Berkower et al., 1989; Steimer et al.,
1991). Envelope glycoprotein gp120 is the main target of
these antibodies (Berkower et al., 1991). Neutralizing hu-
man monoclonal antibodies have been described, which
target conformational sites on gp120 (Buchacher et al.,
1992; Burton et al., 1991; Thali et al., 1991) and a linear
site on gp41 (Muster et al., 1993). However, gp120-based
HIV vaccines have been unable to elicit comparable titers
and breadth of neutralizing antibodies (Graham et al., 1996;
Mascola et al., 1996), and they have generally failed to
demonstrate protection in human vaccine trials (Watanabe,
2003). Limited potency of gp120 remains a major challenge
for HIV-1 vaccine development (Poignard et al., 2001).0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2003.12.017
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enhanced by up to 1000-fold by assembly into virus-like
particles. Successful vaccines such as hepatitis B surface
antigen (HBsAg) (Cabral et al., 1978), L1 protein of human
papilloma virus (Kirnbauer et al., 1992), and rabies vaccine
(Piza et al., 2002) have depended on particle assembly for
vaccine efficacy and protection. In these cases, enhanced
vaccine potency could be manifested by increased antibody
titer as well as improved antibody quality, with more anti-
bodies targeting conformational neutralizing determinants
on the virus.
For HIV antigens, assembly of immunogenic particles
has been a long-term goal, and several carrier proteins have
been tested for particle formation. These include hepatitis B
core antigen (Grene et al., 1997; Patterson et al., 2001),
yeast retrotransposon Ty (Kingsman et al., 1995), retrovirus
gag protein (Lu et al., 1995; Tobin et al., 1996; Wagner et
al., 1998), bovine papilloma virus L1 protein (Liu et al.,
2002), and VSV virions (Rose et al., 2001). In some cases,
native gp120 was not expressed in the particles, and in
others, the antigen density of gp120 per particle was limited.
In the present study, we have expressed gp120 as a fusion
protein with hepatitis B surface antigen (HBsAg). By itself,
HBsAg assembles 22 nm virus-like particles (Ganem and
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expressed together with gp120, the HBsAg-gp120 hybrids
assemble spontaneously and efficiently into virus-like par-
ticles. These particles express gp120 at a lipid–water
interface and display the same conformational epitopes as
found on virions. Enhanced vaccine potency of virus-like
particles was demonstrated by the induction of neutralizing
antibodies after fewer doses than with native gp120.Results
Expression of HBsAg-gp120 hybrids by vaccinia
recombinants
We previously identified a site at amino acid 42 of
gp120 where foreign protein sequences could be linked to
gp120 without disturbing its native folding and receptor
binding (Patterson et al., 2001). We have used this site to
fuse gp120 with a carrier protein capable of self-assembly
(Fig. 1A). Hepatitis B core antigen-gp120 hybrids folded
correctly, but were unable to assemble as particles (Patter-
son et al., 2001). In the current study, we linked gp120 to
HBsAg, using two closely related genes for HBsAg. OneFig. 1. (A) HBsAg-gp120 hybrids expressed by vaccinia recombinants.
Each hybrid consisted of the hemagglutinin leader, followed by amino acids
2–226 of HBsAg (or 1–149 of core antigen) fused to amino acids 42–503
of gp120, with deletion of the V1V2 loop (amino acids 125–205). The viral
gene for HBsAg was used in hybrid MR15, and a codon-optimized
synthetic HBsAg gene was used in MR23. (B) Proposed structure for
HBsAg-gp120 particles. Membrane-spanning HBsAg anchors gp120 to the
particles, producing an array of gp120 molecules at a lipid–water interface.was amplified directly from hepatitis B virus to produce
hybrid MR15. The other, in hybrid MR23, was a synthetic
gene coding for the same amino acid sequence, but used
codons optimized for mammalian gene expression (Haas et
al., 1996). Both HBsAg-gp120 hybrids were expressed in
vaccinia recombinants and tested for gp120 antigenicity and
particle assembly.
Expression of MR15 and MR23 was analyzed by immu-
noblot (Fig. 2). Cell lysates or purified particles were
electrophoresed under reducing conditions and probed with
monoclonal antibody M77, specific for the V3 loop of
gp120 (left panel), or with goat polyclonal antibodies to
HBsAg (right panel). The v55 control expressed native
HBsAg and gave no gp120 band (lane 1). MR15 and
MR23 hybrids, after deletion of the V1V2 domains and
insertion of HBsAg, gave bands the same size (lanes 2 and
3) as native gp120 (lane 6). Because of glycosylation at six
sites, the shorter V1V2 domain (80 amino acids) is predicted
to have nearly the same mass as HBsAg (225 amino acids).
MR23, with optimized codons for part of its sequence,
expressed about twice as much protein as MR15. Purified
MR23 particles contain this band (lane 5), indicating that
HBsAg-gp120 is an intrinsic part of the particles. MR23
also showed a prominent band at about twice the expected
size, indicating dimer formation. Dimers co-purified with
MR23 particles, suggesting that the first step in particle
assembly may be dimer formation, similar to native HBsAg
(Huovila et al., 1992). Western blots of MR15 and MR23
developed with anti-HBsAg showed that the hybrid band
contains surface antigen, as well as gp120. All of the surface
antigen banded at the size of the HBsAg-gp120 hybrid,
indicating that hybrid particles contain gp120 and HBsAg in
a one to one ratio.
Assembly of gp120-rich particles
Assembly of HBsAg-gp120 hybrids was assessed by
sedimentation in a sucrose step gradient (Fig. 3). The
hybrids sedimented at large size and banded at the 20–
50% sucrose interface. In other experiments, the hybrid
banded at a 20–33% sucrose interface (data not shown).
This is denser than native HBsAg, which forms a band at the
10–20% interface, and the band was broader than for native
HBsAg, suggesting greater size heterogeneity. The particles
were much larger than most other proteins, giving signifi-
cant purification at this step. Efficient assembly is indicated
by the fact that nearly all of the antigenic material sedi-
mented at large size, and little or none remained at the top of
the gradient.
Native HBsAg has been purified by banding in CsCl
density gradients (Rizzetto et al., 1980). Under similar
conditions, the HBsAg-gp120 hybrid formed a broad band
at a density of 1.21–1.25 g/ml (Fig. 4). This was slightly
denser than native HBsAg (1.20–1.21 g/ml), but signifi-
cantly lighter than most proteins. Low density of the MR15
particles is consistent with a composition similar to the 25%
Fig. 2. Western blot of HBsAg-gp120 hybrids expressed by recombinant vaccinia virus. Twenty micrograms of protein from infected cell lysates, 3.6 Ag of
sucrose gradient purified MR23 particles, or 120 ng of baculovirus-derived gp120 were reduced with 50 mM dithiothreitol, electrophoresed in a 3–8% gel with
Tris–acetate buffer, transferred to nitrocellulose, and probed with monoclonal antibody M77 to gp120. The v55 control expressed HBsAg alone. MR15 hybrid
expressed in CV-1 cells (lane 2) was compared to MR23 expressed in CV-1 (lane 3) or HeLa cells (lane 4) or to purified MR23 (lane 5). In the right panel, the
same MR15 and MR23 lysates were probed with polyclonal goat antibodies to HBsAg.
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Schneider, 2001). The increased density relative to native
HBsAg may reflect increased protein content due to the
additional gp120 sequence attached to each molecule of
HBsAg.Fig. 3. Sucrose step gradient of MR15. MR15 cell lysate (2.4 ml) was
layered onto a discontinuous sucrose gradient consisting of 50% sucrose
(4.5 ml), 20% sucrose (2.5 ml), and 10% sucrose (2.5 ml), and sedimented
2.5 h at 39000 rpm in a Beckman SW41 rotor. Fractions were assayed for
gp120 content by ELISA. MR15 sedimented at large size, well separated
from most proteins. Little or no antigen remained at the top of the gradient,
indicating efficient assembly of particles.The CsCl banded material was analyzed by electron
microscopy (Fig. 5, left side). The MR15 hybrid formed
spherical particles with a range of sizes between 15 and 30
nm in diameter. The particles resemble native HBsAg
particles (right side). Native HBsAg particles contain
100–200 copies of surface antigen per particle (Aggerbeck
and Peterson, 1985), with surface antigen spanning the lipid
layer two to four times as an intrinsic membrane protein
(Eble et al., 1987; Stirk et al., 1992). On the basis of
observed structural similarities, HBsAg-gp120 particles
may have a comparable number of gp120 molecules arrayed
on the particle surface and anchored to the micelle by
surface antigen. This array of gp120 at the lipid–water
surface of the particles duplicates gp120 on the surface of
HIV-1 virions.
Assembly of mixed particles
Assembly of HBsAg particles occurs in a pre-Golgi
compartment from available precursors (Huovila et al.,
1992). If two forms of HBsAg were expressed in the same
cell, it should be possible to form mixed particles containing
both precursors. We tested this hypothesis by co-expressing
HBsAg-gp120 at the same time as native HBsAg, both at a
multiplicity of infection of three per cell. As shown in Fig.
6, the resulting mixed particles contained gp120, but their
sedimentation profile was shifted dramatically. Instead of
sedimenting in a broad band at the 20–30% sucrose
interface, they now band at the 10–20% interface, the same
as native HBsAg. This shift in sedimentation of gp120
suggests that HBsAg has been incorporated into the same
particles as HBsAg-gp120 and has shifted their density and
composition to be more like native HBsAg particles. As a
Fig. 4. CsCl density gradient of MR15. MR15 culture supernatant was
concentrated by centrifugation, resuspended in PBS, and banded in CsCl
(upper panel). An HBsAg control was banded separately (lower panel).
HBsAg particles banded at a density of 1.20–1.21 g/ml, consistent with a
lipid content of 25%. MR15 banded at 1.21–1.25 g/ml, although most other
proteins were denser.
Fig. 6. Co-expression of two antigens produces mixed particles. CV-1 cells
were infected with MR23 (optimized HBsAg-gp120) without or with
MR21 (optimized HBsAg alone) at a multiplicity of infection of three each.
Cell lysates were sedimented through sucrose gradients, and fractions were
assayed, using monoclonals specific for gp120 or HBsAg. By itself, MR23
banded at the 20–30% sucrose interface. Co-infection with MR21 shifted
the entire gp120 peak to the 10–20% interface, where native HBsAg also
bands.
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mixed with HBsAg particles before centrifugation did not
shift their sedimentation profile (not shown).Fig. 5. Electron microscopy of MR15 particles. Peak fractions from the CsCl gra
analyzed by electron microscopy at a magnification of 100000 . HBsAg-gp12
panel). The scale bar indicates 100 nm for both samples.Native conformation of gp120 in particles
MR15 particles were characterized with a panel of
human neutralizing monoclonal antibodies specific for
conformational or discontinuous epitopes on gp120. Anti-
bodies F105 and 1b12 are specific for the CD4 binding site
and depend on the native conformation of gp120 (Thali et
al., 1991), while antibody 2G12 is specific for a discon-
tinuous epitope that depends on glycosylation (Wyatt et al.,
1998). As shown in Fig. 7, these antibodies all bound
particulate gp120 with high affinity, similar to monomeric
gp120, indicating that conformational sites recognized by
these antibodies are present in the particles and in mono-dient (Fig. 4) were negatively stained with 2% methylamine tungstate and
0 hybrid MR15 (left panel) is compared to native HBsAg particles (right
Fig. 7. Characterization of gp120 particles with monoclonal antibodies to conformational sites. Microtiter plates were coated with 0.6 Ag/ml MR15 (left panel)
or 1 Ag/ml gp120 (right panel), blocked with BSA, and incubated with monoclonal antibodies to the CD4 binding site (1b12 and F105) or to another
conformation-dependent neutralizing site (2G12). For each monoclonal, binding to gp120 particles was determined when the binding to monomeric gp120
reached a plateau of 2 OD.
Fig. 8. CD4-Ig binding to gp120 particles. CD4-Ig was incubated in
microtiter wells coated with gp120, MR15, or HBsAg, and binding was
detected with enzyme-labeled goat anti-human IgG (Fc specific). CD4-Ig
bound particulate gp120 with high affinity and specificity.
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mouse monoclonals M77 and D47 (see below) to the V3
loop bound equally well, although control monoclonal
M107 (specific for the missing V1V2 region) did not bind.
Particulate gp120 expressed all conformational neutralizing
epitopes tested. This is important for a vaccine antigen,
because a vaccine lacking these epitopes would be unable
to elicit antibodies to these broadly shared neutralizing
sites.
The conformation of gp120 in particles was probed with
CD4-Ig, whose binding depends on the native conformation
of the CD4 binding site (Kowalski et al., 1987). CD4-Ig
binding to MR15 particles was comparable to monomeric
gp120, and both were half-maximal at about 2 nM (0.2 Ag/
ml in Fig. 8). Specificity for gp120 in the hybrid was shown
by the failure to bind HBsAg alone. The CD4 binding site is
an important target for broadly cross-reactive neutralizing
antibodies (Berkower et al., 1991; Burton et al., 1991;
Steimer et al., 1991; Thali et al., 1991), so it is an essential
feature of any particle vaccine. CD4-Ig binding to gp120
particles was blocked by pre-incubation with monoclonal
antibody Q4120 (Healey et al., 1990), which binds the
Leu3a determinant (not shown). This result indicates that
gp120 in particles binds the same site on CD4 as do gp120
monomers.
Antibodies specific for different assembled and matura-
tional forms of gp120 were used to assess the status of
gp120 in particles. Monoclonal M15 is specific for gp120
monomers and binds gp120 early after synthesis. But as
gp120 matures, it assembles into trimers, and M15 binding
is lost (Otteken et al., 1996). Failure to bind M15 is a
measure of gp120 assembly into trimers, as found in viral
spikes (Weiss et al., 1990). Monoclonal D47 binds all
maturational forms of gp120, from monomer to trimer. Asshown in Fig. 9 (right side), both monoclonals bound
monomeric gp120. However, although D47 bound gp120
particles, M15 did not (left side). Lack of M15 binding
suggests a qualitative difference between gp120 particles
and free monomers.
In a control experiment, M15 bound a core antigen-
gp120 hybrid as well as native gp120, but not the HBsAg-
Fig. 9. The assembled state of gp120 in particles was probed with monoclonal M15, which binds monomers but not assembled trimers of gp120, and
monoclonal D47, which binds all forms of gp120. Wells were coated with MR15 (0.6 Ag/ml) or gp120 (0.8 Ag/ml). M15 bound gp120 monomers but not gp120
particles, suggesting that gp120 particles are qualitatively different from free gp120. Antibody concentration is expressed as 1/dilution of culture supernatant.
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has the same V1V2 deletion as the HBsAg-gp120 hybrid,
but it failed to assemble particles (Patterson et al., 2001).
Thus, failure of M15 binding was not due to the V1V2Fig. 10. Monoclonal M15 binding to core antigen-gp120 hybrid vs. HBsAg-gp
assembled (HBsAg hybrid) and the other is not (core antigen hybrid). M15 binds th
particles. Antibody concentration is expressed as dilution of M15 culture supernadeletion, but was due to particle formation. The lack of M15
binding suggests that gp120 particles are qualitatively
different from and are not simply the sum of gp120 mono-
mers. Packing interactions among neighboring gp120 mol-120 hybrid. Both hybrids share the identical V1V2 deletion, but one is
e unassembled gp120-core antigen hybrid, but not assembled gp120-HBsAg
tant.
Fig. 11. Neutralizing antibodies elicited by HBsAg-gp120 hybrids. Rabbits were immunized with 10 Ag of gp120 particles or monomeric gp120 expressed by
baculovirus. After the second dose, neutralizing activity was measured against HIV pseudovirions bearing the homologous envelope glycoproteins.
Neutralizing antibodies appeared earlier in rabbits immunized with gp120 particles.
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binding, just as they do in mature HIV virions.
Neutralizing antibodies
The gene coding for HBsAg-gp120 hybrid MR23 was
cloned into a baculovirus vector and expressed by infecting
insect cells (Luckow et al., 1993). The resulting gp120
particles were purified on a sucrose gradient and injected
into rabbits in Freund’s adjuvant. Rabbit neutralizing anti-
bodies were measured in a single-step infectivity assay
against HIV-1 pseudovirions expressing luciferase (Connor
et al., 1995). As shown in Fig. 11, neutralizing antibodies
appeared after two doses of the gp120 particle vaccine.
Monomeric gp120, also expressed by baculovirus, required
three doses to elicit comparable levels of neutralizing anti-
bodies. Rabbit neutralizing activity against the homologous
strain nearly equaled that of HIV immune globulin from
infected people.Discussion
For many viral antigens, particle formation is accompa-
nied by a significant increase in vaccine potency. We haveincorporated gp120 into virus-like particles to enhance its
vaccine potency. In our construct, gp120 was fused to a
carrier protein HBsAg that was capable of spontaneous
assembly into particles. As the HBsAg part of the fusion
protein assembled, it incorporated gp120 into the particles.
Assembly was an efficient process, with very little gp120
antigen remaining as monomers. The surprising finding
was that a small protein like HBsAg (25 kDa) could
assemble particles, even when fused to a much larger
protein like gp120 (95 kDa with a V1V2 deletion). As-
sembly may depend more on the flexibility of HBsAg and
its molecular compatibility with gp120 than on relative
size. The flexibility of HBsAg is suggested by its ability to
assume different forms in nature, including 42 nm Dane
particles (hepatitis B virus), 22 nm spherical particles, rods
with a diameter of 22 nm (Ganem and Schneider, 2001),
and even 32 nm virions of hepatitis y virus (Rizzetto et al.,
1980).
The topology of HBsAg in a lipid bilayer may be crucial
to the formation of stable particles rich in gp120. Accord-
ing to the current model (Stirk et al., 1992), HBsAg is an
intrinsic membrane protein that spans the membrane four
times, allowing it to anchor gp120 to the particles (Fig.
1B). By expressing gp120 on a lipid surface, the particles
recreate the natural milieu of gp120 on HIV virions. Native
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(Aggerbeck and Peterson, 1985). Although HBsAg-gp120
particles are roughly the same size, their greater heteroge-
neity suggests that they may vary about an average content
of 100 HBsAg-gp120 molecules per particle. The model
also predicts that the amino and carboxyl ends of HBsAg,
as well as a short hydrophilic sequence in the middle,
are exposed on the surface of particles, which agrees with
the limited protease sensitivity of HBsAg, except at
these sites (Sonveaux et al., 1994). The topology may
explain the ability to link other antigens to the amino end
(Bruss and Ganem, 1991; Stoute et al., 1997; Valenzuela et
al., 1985), the middle hydrophilic sequence (Delpeyroux
et al., 1986; Eckhart et al., 1996), or the carboxyl end
(Bisht et al., 2002) of HBsAg, while still forming stable
particles, as well as our success in attaching gp120 at the
carboxyl end.
The maturation pathways for HBsAg and gp120 are
similar, allowing particle assembly in the pre-Golgi com-
partments (Huovila et al., 1992) and folding and glycosyl-
ation in the Golgi. Compatibility in intracellular trafficking
and membrane localization may also determine which
proteins can be incorporated into HBsAg particles. Other
enveloped viral glycoproteins smaller than gp120 have
assembled into HBsAg particles, including glycoprotein D
of herpes simplex virus type 1 (Valenzuela et al., 1985) and
dengue virus envelope protein (Bisht et al., 2002). This is
the first report of native gp120 assembling into HBsAg
particles.
Once incorporated into particles, gp120 demonstrated
several properties that could contribute to vaccine potency.
First, the CD4 binding domain is intact, as shown by
binding CD4 with high affinity, as well as two human
monoclonal antibodies specific for this site. This site is an
important target for neutralizing antibodies made by
infected humans (Berkower et al., 1991; Steimer et al.,
1991), and it is broadly shared among diverse HIV-1
isolates. Mutational escape at this site may be difficult,
because it performs the essential viral function of receptor
binding. In addition, neutralization targeting this site may
proceed by an efficient mechanism that causes viral inacti-
vation when as few as 2% of sites are bound by CD4-Ig
(Berkower et al., 1996).
Second, gp120 particles bound well to every neutraliz-
ing monoclonal tested, including antibodies specific for
conformational sites such as F105, 1b12, and 2G12.
Particulate gp120 has multiple neutralizing epitopes, each
in the native conformation. This should help broaden the
antibody response to non-vaccine strains, because cross-
reactive neutralizing antibodies are often specific for con-
formational sites on gp120 (Berkower et al., 1989, 1991).
It may also increase the neutralizing titer, because a
combination of antibodies to different epitopes can produce
additive or even synergistic neutralizing effects on HIV-1
(Li et al., 1997). A combination of neutralizing monoclonal
antibodies to these determinants (plus monoclonal 2F5against gp41) completely protected rhesus macaques
against SHIV challenge (Baba et al., 2000; Mascola et
al., 2000). By eliciting active immunity to these determi-
nants, a gp120 particle vaccine could achieve one impor-
tant goal of vaccination, which is to elicit broadly cross-
reactive neutralizing antibodies.
Third, as shown in the model (Fig. 1B), the overall
design of gp120 particles resembles the surface of HIV
virus, with about 100 copies of gp120 arrayed on the
surface of each particle at a lipid–water interface. Oligo-
meric forms of gp120 have shown activity as vaccine
antigens. Native gp140 trimers, corresponding to the HIV-
1 viral spike, have elicited novel antibodies (Earl et al.,
1994) and have protected rhesus macaques against SHIV
challenge (Earl et al., 2001). Aldrithiol-2-inactivated HIV-1
virions, with 21–42 gp120 molecules per particle (Arthur et
al., 1998; Chertova et al., 2002), have boosted neutralizing
antibodies and have helped to control viremia after a
pathogenic SHIV challenge (Willey et al., 2003). The
greater antigen density of HBsAg-gp120 particles, due to
more antigen on a smaller particle, may contribute even
more to vaccine potency.
Each of these factors may contribute to the enhanced
potency of gp120 particles, as shown by their ability to elicit
neutralizing antibodies after fewer doses of vaccine. Par-
ticles may enhance vaccine potency by improving the
quantity and quality of antibodies elicited. Immunization
with particles is believed to deliver a strong stimulus to B
cells through cross-linking of surface immunoglobulin,
which also makes them more responsive to T cell help
(Bachmann and Zinkernagel, 1997). In addition, because
enveloped particles so closely resemble enveloped virus, a
greater proportion of antibodies may bind conformational
sites on the virus, including neutralizing determinants.
Enveloped particles may be a good substitute for inactivated
viral vaccines, because they avoid the risk of infection due
to incomplete inactivation.
Our finding that co-expression of two vaccinia recombi-
nants can produce mixed HBsAg particles is consistent with
earlier observations that co-expression of small- and middle-
sized HBsAg produced mixed particles (Cheng and Moss,
1987), as did co-expression of surface antigens from human
and woodchuck hepatitis viruses (Gerhardt and Bruss,
1995). This would allow expression of two different viral
proteins or two different gp120 variants in the same particle.
It also raises the interesting possibility of combining anti-
gens and cytokines in the same particle to enhance or
modulate the immune response to the antigen. For example,
DNA vaccines linking HBsAg with IL-2 have been reported
to enhance the immune response to HBsAg (Chow et al.,
1997).
Our results indicate that envelope glycoproteins nearly as
large as gp120 can be efficiently incorporated into HBsAg-
containing virus-like particles, while retaining their native
conformation. By creating an array of gp120 molecules in
their natural milieu on a lipid surface, these particles can
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immunization.Materials and methods
Cells
CV-1, HeLa, and tk-cells were obtained from Dr. Michael
Merchlinsky (CBER, Bethesda, MD) and were grown in
Dulbecco’s modified medium supplemented with 10% FCS,
penicillin and streptomycin, and glutamine.
Proteins and antibodies
HBsAg was a gift from Dr. James Shih (NIH blood
bank), gp120 expressed in baculovirus was from Protein
Sciences (Meriden, CT) (Cochran et al., 1987), and CD4-Ig
was a gift from Dr. Phil Berman (Genentech, South San
Francisco, CA) (Capon et al., 1989).
Mouse monoclonal antibodies to the V3 loop of gp120
included M77 (Pal et al., 1992) from Advanced Biotech-
nologies (Columbia, MD) and D47 (Otteken et al., 1996)
from Dr. Pat Earl (NIAID, NIH). Mouse monoclonal M15
(Otteken et al., 1996) was specific for gp120 monomers
and would not bind assembled forms. Human neutralizing
monoclonal antibodies to gp120 were obtained from the
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH, and included F105 from Dr.
Marshall Posner (Posner et al., 1993; Thali et al.,
1991), IgG1 b12 from Dr. Dennis Burton and Carlos
Barbas (Burton et al., 1991), both specific for the CD4
binding site, and 2G12 from Dr. Hermann Katinger
(Buchacher et al., 1992), specific for a carbohydrate-
dependent site. Affinity-purified goat anti-human IgG
antibodies and goat anti-mouse IgG antibodies coupled
to alkaline phosphatase were obtained from Cappel Labs
(West Chester, PA).
Generation of recombinant vaccinia virus
DNA coding for Hepatitis B surface antigen was PCR
amplified from pECO63 (ATCC, Manassas, VA) usingFig. 12. Nucleotide and amino acid sequences of the synthetic HBsAg gene based
one was substituted near the amino end (underlined). This gene was expressed inprimers CCGAATTCATCACAT CAGGATTCCTAGG
(RB5) and CAGGTACCCAATGTATACCCAGAGACA
(RB6). The 690 bp product was cut with EcoRI and KpnI
and ligated into plasmid MR9 described previously (Patter-
son et al., 2001), in place of the gene for core antigen. The
resulting plasmid, MR15 (Fig. 1), codes for the influenza
hemagglutinin leader, followed by residues 2–226 of hepa-
titis B surface antigen in tandem with HIV IIIB envelope
glycoprotein gp120 residues 42 – 125 and 205–503,
corresponding to deletion of the V1V2 loops. This deletion
has no effect on CD4 binding (Pollard et al., 1992). At the
HBsAg-gp120 junction, the last four amino acids of HBsAg,
WVYI, replace a homologous sequence in gp120 VTWIYY.
Recombinant vaccinia virus was generated from plasmid
MR15 by transformation and co-infection of CV-1 cells with
wild-type vaccinia virus (Earl and Moss, 1991). Vaccinia
recombinants were grown on tk-monolayers under BudR
selection. Beta-galactosidase positive plaques were expand-
ed twice on tk-cells grown in 12-well plates. Cell lysates
were screened for gp120 expression by antigen capture
ELISA on microtiter plates coated with mouse monoclonal
M77. Bound gp120 hybrid was detected with HIV-Ig
(pooled human antibodies to HIV-1), followed by enzyme-
labeled goat anti-human IgG. Vaccinia recombinants
expressing gp120 hybrids were plaque purified at least three
times and expanded on CV-1 cells.
Construction of a synthetic gene for HBsAg using optimized
codons
A fully synthetic HBsAg gene was generated, in which
optimized codons were substituted for viral codons (Haas et
al., 1996). It was made by PCR amplification of a series of
40-base pair primers with 20 base overlaps (Stemmer et al.,
1995). The resulting full-length gene was cloned, and four
clones were sequenced. One had a single base error that was
repaired by PCR, resulting in a complete HBsAg gene
optimized for protein expression (Fig. 12). Synthesis and
sequence analysis were performed by ATG Laboratories
(Eden Prairie, MN). The synthetic gene was cut with EcoRI
and KpnI and inserted in place of natural HBsAg in plasmid
MR15 to create MR23. MR23 was used to generate vaccinia
recombinants as described above.on optimized codons. Five amino acids were added at the carboxyl end, and
tandem with gp120 in the MR23 hybrid.
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Discontinuous sucrose gradients consisted of layers of 50
or 33%, 20%, and 10% sucrose in ultracentrifuge tubes.
Lysates were prepared from about 200  106 cells by
freezing and thawing cells three times, followed by sonica-
tion for 30 s and centrifugation for 10 min at 12000 rpm in a
Sorvall SS-34 rotor. The clarified supernatant (2.5 ml) was
layered onto sucrose and sedimented 2.5 h at 39000 rpm in a
Beckman SW41 rotor. Fractions were collected from the
bottom and assayed for antigen by ELISA and for protein by
BCA reagent (Pierce Chemical, Rockford, IL). Peak frac-
tions were pooled, diluted in PBS, and centrifuged overnight
at 32000 rpm in a Beckman 35 rotor to concentrate the
particles. Pellets were resuspended in PBS and stored frozen.
CsCl gradients
Culture supernatant from 1.8  108 cells expressing
MR15 was clarified by centrifugation for 10 min at 12000
rpm in a Sorvall GSA rotor, followed by pelleting in a
Beckman 45 Ti rotor for 2 h at 40000 rpm. The pellet was
resuspended in PBS, added to CsCl at a final concentration
of 1.70 M, and centrifuged 18 h at 62000 rpm in a Beckman
NVT 90 rotor. Fractions were collected and assayed for
gp120 content by ELISA.
ELISA assay of gp120
Sucrose gradient fractions were diluted 1:8 in PBS and
added to wells of flexible microtiter plates (Falcon 3912).
These were incubated overnight at 4 jC, then blocked with
1% BSA. Detection of gp120 was with monoclonal antibody
2G12, at 1 Ag/ml for 2 h at room temperature. Plates were
washed in PBS + 0.1% Tween + 0.1% BSA + 0.02% sodium
azide, and bound antibody was detected with alkaline phos-
phatase labeled, affinity purified, goat anti-human IgG. After
1 3/4 h, the plates were washed and phosphatase substrate
(Sigma 104) was added. Antigen content, read as OD410 in a
Dynatech MR5000 plate reader, was compared to a gp120
standard curve to determine antigen content in micrograms.
To measure the binding of monoclonal antibodies or
CD4-Ig to HBsAg-gp120 particles, ELISA plates were
coated overnight at 4 jC with sucrose-purified hybrid at
0.6 Ag/ml, or baculo-derived gp120 at 1 Ag/ml, followed by
blocking with bovine serum albumin at 10 mg/ml. Serial
dilutions of each monoclonal antibody were added to each
well and incubated as described above, followed by detec-
tion with affinity-purified goat anti-human IgG coupled to
alkaline phosphatase.
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